Nanotechnology-mediated precision delivery of mRNA
Source abstract
Abstract
Messenger RNA-based therapeutics have been successful in preventing and treating various diseases. Nonetheless, these therapies still face difficulties in achieving specific delivery to organs, tissues and cells, which are exacerbated by the need to overcome multilevel biological barriers and intrinsically complex physiological disease characteristics. Several approaches are being developed to overcome these challenges, including optimizing administration routes, enhancing targeting abilities and facilitating responsive release. These tailored design strategies have been utilized in applications including mRNA vaccines, protein replacement and gene editing for enhanced precision therapies. This Review discusses various heterogeneous barriers for mRNA delivery and nanocarrier-mediated mRNA precision-delivery strategies, and highlights their uses in biomedical applications. Moreover, we discuss current limitations and future perspectives to accelerate the development of precision mRNA delivery to address current clinical needs.
Source: europepmc · Quality: candidate unverified · Source record ↗
Research context
OpenAlex topics: RNA Interference and Gene Delivery · Virus-based gene therapy research · Nanoparticle-Based Drug Delivery
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
References (100+)
Show source-provided references
1. Liu, C. et al. mRNA-based cancer therapeutics. Nat. Rev. Cancer 23, 526–543 (2023).10.1038/s41568-023-00586-2 ↗
2. Wang, C., Zhao, C., Wang, W., Liu, X. & Deng, H. Biomimetic noncationic lipid nanoparticles for mRNA delivery. Proc. Natl Acad. Sci. USA 120, e2311276120 (2023).10.1073/pnas.2311276120 ↗
3. Ibba, M. L., Ciccone, G., Esposito, C. L., Catuogno, S. & Giangrande, P. H. Advances in mRNA non-viral delivery approaches. Adv. Drug Deliv. Rev. 177, 113930 (2021).10.1016/j.addr.2021.113930 ↗
4. Yuan, M. J. et al. mRNA nanodelivery systems: targeting strategies and administration routes. Biomater. Res. 27, 90 (2023).10.1186/s40824-023-00425-3 ↗
5. Chaudhary, N., Weissman, D. & Whitehead, K. A. mRNA vaccines for infectious diseases: principles, delivery and clinical translation. Nat. Rev. Drug Discov. 20, 817–838 (2021).10.1038/s41573-021-00283-5 ↗
6. Sun, B. et al. Engineering nanoparticle toolkits for mRNA delivery. Adv. Drug Deliv. Rev. 200, 115042 (2023).10.1016/j.addr.2023.115042 ↗
7. Huang, P., Deng, H. Z., Wang, C. R., Zhou, Y. F. & Chen, X. Y. Cellular trafficking of nanotechnology-mediated mRNA delivery. Adv. Mater. 36, e2307822 (2023).10.1002/adma.202307822 ↗
8. Zhao, C., Wang, C., Shan, W., Wang, W. & Deng, H. Fusogenic lipid nanovesicle for biomacromolecular delivery. Nano Lett. 24, 8609–8618 (2024).10.1021/acs.nanolett.4c01709 ↗
9. Liu, X., Huang, P., Yang, R. & Deng, H. mRNA cancer vaccines: construction and boosting strategies. ACS Nano 17, 19550–19580 (2023).10.1021/acsnano.3c05635 ↗
10. Huang, P. et al. An integrated polymeric mRNA vaccine without inflammation side effects for cellular immunity mediated cancer therapy. Adv. Mater. 35, 2207471 (2023).10.1002/adma.202207471 ↗
11. Rohner, E., Yang, R., Foo, K. S., Goedel, A. & Chien, K. R. Unlocking the promise of mRNA therapeutics. Nat. Biotechnol. 40, 1586–1600 (2022).10.1038/s41587-022-01491-z ↗
12. Kim, J., Eygeris, Y., Ryals, R. C., Jozić, A. & Sahay, G. Strategies for non-viral vectors targeting organs beyond the liver. Nat. Nanotechnol. 19, 428–427 (2023).10.1038/s41565-023-01563-4 ↗
13. Sago, C. D. et al. Augmented lipid-nanoparticle-mediated in vivo genome editing in the lungs and spleen by disrupting Cas9 activity in the liver. Nat. Biomed. Eng. 6, 157–167 (2022).10.1038/s41551-022-00847-9 ↗
14. Fei, Y. et al. Simplified lipid nanoparticles for tissue- and cell-targeted mRNA delivery facilitate precision tumor therapy in a lung metastasis mouse model. Adv. Mater. 36, 2409812 (2024).10.1002/adma.202409812 ↗
15. Cheng, Q. et al. Selective organ targeting (SORT) nanoparticles for tissue-specific mRNA delivery and CRISPR–Cas gene editing. Nat. Nanotechnol. 15, 313–320 (2020).10.1038/s41565-020-0669-6 ↗
16. Mitchell, M. J. et al. Engineering precision nanoparticles for drug delivery. Nat. Rev. Drug Discov. 20, 101–124 (2021).10.1038/s41573-020-0090-8 ↗
17. Gao, J. et al. Precision drug delivery to the central nervous system using engineered nanoparticles. Nat. Rev. Mater. 9, 567–588 (2024).10.1038/s41578-024-00695-w ↗
18. Waheed, S. et al. Engineering nano-drug biointerface to overcome biological barriers toward precision drug delivery. J. Nanobiotechnol. 20, 395 (2022).10.1186/s12951-022-01605-4 ↗
19. Wang, J., Li, Y. & Nie, G. Multifunctional biomolecule nanostructures for cancer therapy. Nat. Rev. Mater. 6, 766–783 (2021).10.1038/s41578-021-00315-x ↗
20. Tenzer, S. et al. Rapid formation of plasma protein corona critically affects nanoparticle pathophysiology. Nat. Nanotechnol. 8, 772–781 (2013).10.1038/nnano.2013.181 ↗
21. Dilliard, S. A. & Siegwart, D. J. Passive, active and endogenous organ-targeted lipid and polymer nanoparticles for delivery of genetic drugs. Nat. Rev. Mater. 8, 282–300 (2023).10.1038/s41578-022-00529-7 ↗
22. Zhao, Z. M., Ukidve, A., Kim, J. & Mitragotri, S. Targeting strategies for tissue-specific drug delivery. Cell 181, 151–167 (2020).10.1016/j.cell.2020.02.001 ↗
23. Hennigs, J. K., Matuszcak, C., Trepel, M. & Körbelin, J. Vascular endothelial cells: heterogeneity and targeting approaches. Cells 10, 2712 (2021).10.3390/cells10102712 ↗
24. Poon, W., Kingston, B. R., Ouyang, B., Ngo, W. & Chan, W. C. W. A framework for designing delivery systems. Nat. Nanotechnol. 15, 819–829 (2020).10.1038/s41565-020-0759-5 ↗
25. Hu, M., Li, X., You, Z., Cai, R. & Chen, C. Physiological barriers and strategies of lipid-based nanoparticles for nucleic acid drug delivery. Adv. Mater. 36, 2303266 (2024).10.1002/adma.202303266 ↗
26. Sahay, G., Alakhova, D. Y. & Kabanov, A. V. Endocytosis of nanomedicines. J. Control. Release 145, 182–195 (2010).10.1016/j.jconrel.2010.01.036 ↗
27. Sousa de Almeida, M. et al. Understanding nanoparticle endocytosis to improve targeting strategies in nanomedicine. Chem. Soc. Rev. 50, 5397–5434 (2021).10.1039/D0CS01127D ↗
28. Zhong, Q. et al. Structural and componential design: new strategies regulating the behavior of lipid-based nanoparticles in vivo. Biomater. Sci. 11, 4774–4788 (2023).10.1039/D3BM00387F ↗
29. Kong, H. et al. Membrane-fusogenic biomimetic particles: a new bioengineering tool learned from nature. J. Mater. Chem. B 10, 6841–6858 (2022).10.1039/D2TB00632D ↗
30. Yu, H., Dyett, B. P., Drummond, C. J. & Zhai, J. Ionizable lipid nanoparticles for mRNA delivery: internal self-assembled inverse mesophase structure and endosomal escape. Acc. Chem. Res. 58, 3210–3222 (2025).10.1021/acs.accounts.5c00522 ↗
31. Binici, B., Rattray, Z., Zinger, A. & Perrie, Y. Exploring the impact of commonly used ionizable and pegylated lipids on mRNA-LNPs: a combined in vitro and preclinical perspective. J. Control. Release 377, 162–173 (2025).10.1016/j.jconrel.2024.11.010 ↗
32. He, Y. et al. Morphological changes induced by buffer exchange during preparation of mRNA-lipid nanoparticles occur in a stepwise manner as pH is elevated. Mol. Ther. 33, 101578 (2025).
33. Zheng, L., Bandara, S. R., Tan, Z. & Leal, C. Lipid nanoparticle topology regulates endosomal escape and delivery of RNA to the cytoplasm. Proc. Natl Acad. Sci. USA 120, e2301067120 (2023).10.1073/pnas.2301067120 ↗
34. Wu, Y., Yu, S. & de Lázaro, I. Advances in lipid nanoparticle mRNA therapeutics beyond COVID-19 vaccines. Nanoscale 16, 6820–6836 (2024).10.1039/D4NR00019F ↗
35. Felgner, J. et al. Lipid nanoparticle development for a fluvid mRNA vaccine targeting seasonal influenza and SARS-CoV-2. npj Vaccines 10, 123 (2025).10.1038/s41541-025-01153-6 ↗
36. Desantis, J. et al. PROTACs bearing piperazine-containing linkers: what effect on their protonation state? RSC Advances 12, 21968–21977 (2022).10.1039/D2RA03761K ↗
37. Zhang, R.-H., Guo, H.-Y., Deng, H., Li, J. & Quan, Z.-S. Piperazine skeleton in the structural modification of natural products: a review. J. Enzyme Inhib. Med. Chem. 36, 1165–1197 (2021).10.1080/14756366.2021.1931861 ↗
38. Porte, S., V, V. & Sengupta, D. A molecular view of lipid nanoparticles: insights into their morphology and structural plasticity. Small 21, e05404 (2025).10.1002/smll.202505404 ↗
39. Tang, X., Zhang, Y. & Han, X. Ionizable lipid nanoparticles for mRNA delivery. Adv. NanoBiomed. Res. 3, 2300006 (2023).10.1002/anbr.202300006 ↗
40. Kulkarni, J. A., Witzigmann, D., Chen, S., Cullis, P. R. & van der Meel, R. Lipid nanoparticle technology for clinical translation of siRNA therapeutics. Acc. Chem. Res. 52, 2435–2444 (2019).10.1021/acs.accounts.9b00368 ↗
41. Kulkarni, J. A., Witzigmann, D., Leung, J., Tam, Y. Y. C. & Cullis, P. R. On the role of helper lipids in lipid nanoparticle formulations of siRNA. Nanoscale 11, 21733–21739 (2019).10.1039/C9NR09347H ↗
42. Su, K. et al. Reformulating lipid nanoparticles for organ-targeted mRNA accumulation and translation. Nat. Commun. 15, 5659 (2024).10.1038/s41467-024-50093-7 ↗
43. Eygeris, Y., Gupta, M., Kim, J. & Sahay, G. Chemistry of lipid nanoparticles for RNA delivery. Acc. Chem. Res. 55, 2–12 (2022).10.1021/acs.accounts.1c00544 ↗
44. Khunsuk, P. -o, Pongma, C., Palaga, T. & Hoven, V. P. Zwitterionic polymer-decorated lipid nanoparticles for mRNA delivery in mammalian cells. Biomacromolecules 24, 5654–5665 (2023).10.1021/acs.biomac.3c00649 ↗
45. Li, S., Wang, W. & Yu, X. A perspective of engineered lipids and liposomes: chemical design and functional application based on therapeutic safety. Chem. Mater. 35, 4587–4597 (2023).10.1021/acs.chemmater.3c00842 ↗
46. Mashal, M. et al. Comparative analysis of lipid-peptide nanoparticles prepared via microfluidics, reverse phase evaporation, and ouzo techniques for efficient plasmid DNA delivery. Eur. J. Pharm. Biopharm. 201, 114385 (2024).10.1016/j.ejpb.2024.114385 ↗
47. Yu, M. et al. in Microfluidics in Pharmaceutical Sciences: Formulation, Drug Delivery, Screening, and Diagnostics (eds Lamprou, D. A. & Weaver, E.) 395–420 (Springer Nature, 2024).
48. Huang, P., Deng, H., Zhou, Y. & Chen, X. The roles of polymers in mRNA delivery. Matter 5, 1670–1699 (2022).10.1016/j.matt.2022.03.006 ↗
49. Yang, W., Mixich, L., Boonstra, E. & Cabral, H. Polymer-based mRNA delivery strategies for advanced therapies. Adv. Healthc. Mater. 12, 2202688 (2023).10.1002/adhm.202202688 ↗
50. Moreno Herrero, J. et al. Compact polyethylenimine-complexed mRNA vaccines. Nat. Nanotechnol. 20, 1323–1331 (2025).10.1038/s41565-025-01961-w ↗
51. Yang, S. et al. Fluorinated polyethyleneimine vectors with serum resistance and adjuvant effect to deliver LMP2 mRNA vaccine for nasopharyngeal carcinoma therapy. Acta Biomater. 192, 340–352 (2025).10.1016/j.actbio.2024.12.022 ↗
52. Putnam, D. Polymers for gene delivery across length scales. Nat. Mater. 5, 439–451 (2006).10.1038/nmat1645 ↗
53. Lostalé-Seijo, I. & Montenegro, J. Synthetic materials at the forefront of gene delivery. Nat. Rev. Chem. 2, 258–277 (2018).10.1038/s41570-018-0039-1 ↗
54. Moffett, H. F. et al. Hit-and-run programming of therapeutic cytoreagents using mRNA nanocarriers. Nat. Commun. 8, 389 (2017).10.1038/s41467-017-00505-8 ↗
55. McKinlay, C. J., Benner, N. L., Haabeth, O. A., Waymouth, R. M. & Wender, P. A. Enhanced mRNA delivery into lymphocytes enabled by lipid-varied libraries of charge-altering releasable transporters. Proc. Natl Acad. Sci. USA 115, E5859–E5866 (2018).10.1073/pnas.1805358115 ↗
56. Vazdar, M. et al. Arginine “magic”: guanidinium like-charge ion pairing from aqueous salts to cell penetrating peptides. Acc. Chem. Res. 51, 1455–1464 (2018).10.1021/acs.accounts.8b00098 ↗
57. Wang, D. et al. Functionalizing DNA nanostructures with natural cationic amino acids. Bioact. Mater. 6, 2946–2955 (2021).
58. Xiao, W. et al. Advance in peptide-based drug development: delivery platforms, therapeutics and vaccines. Signal Transduct. Target. Ther. 10, 74 (2025).10.1038/s41392-024-02107-5 ↗
59. Wang, Z., Zhou, J., Su, R., Qi, W. & Wang, Y. Design of peptide-based gene delivery systems to overcome biological barriers. J. Mater. Chem. B 13, 12738–12764 (2025).10.1039/D5TB00766F ↗
60. Chen, Z. et al. An mRNA vaccine elicits STING-dependent antitumor immune responses. Acta Pharm. Sin. B 13, 1274–1286 (2023).10.1016/j.apsb.2022.11.013 ↗
61. Nakase, I. et al. Efficient intracellular delivery of nucleic acid pharmaceuticals using cell-penetrating peptides. Acc. Chem. Res. 45, 1132–1139 (2012).10.1021/ar200256e ↗
62. Liong, M. et al. Multifunctional inorganic nanoparticles for imaging, targeting, and drug delivery. ACS Nano 2, 889–896 (2008).10.1021/nn800072t ↗
63. Zou, Y., Huang, B., Cao, L., Deng, Y. & Su, J. Tailored mesoporous inorganic biomaterials: assembly, functionalization, and drug delivery engineering. Adv. Mater. 33, 2005215 (2021).10.1002/adma.202005215 ↗
64. Wang, J. et al. Engineered mRNA delivery systems for biomedical applications. Adv. Mater. 36, 2308029 (2024).10.1002/adma.202308029 ↗
65. Yang, Z. et al. Large-scale generation of functional mRNA-encapsulating exosomes via cellular nanoporation. Nat. Biomed. Eng. 4, 69–83 (2020).10.1038/s41551-019-0485-1 ↗
66. Hou, X., Zaks, T., Langer, R. & Dong, Y. Lipid nanoparticles for mRNA delivery. Nat. Rev. Mater. 6, 1078–1094 (2021).10.1038/s41578-021-00358-0 ↗
67. Meyer, R. A., Neshat, S. Y., Green, J. J., Santos, J. L. & Tuesca, A. D. Targeting strategies for mRNA delivery. Mater Today Adv. 14, 100240 (2022).10.1016/j.mtadv.2022.100240 ↗
68. Rizvi, F. et al. Murine liver repair via transient activation of regenerative pathways in hepatocytes using lipid nanoparticle-complexed nucleoside-modified mRNA. Nat. Commun. 12, 613 (2021).10.1038/s41467-021-20903-3 ↗
69. Loughrey, D. & Dahlman, J. E. Non-liver mRNA delivery. Acc. Chem. Res. 55, 13–23 (2022).10.1021/acs.accounts.1c00601 ↗
70. Qiu, M. et al. Lung-selective mRNA delivery of synthetic lipid nanoparticles for the treatment of pulmonary lymphangioleiomyomatosis. Proc. Natl Acad. Sci. USA 119, e2116271119 (2022).10.1073/pnas.2116271119 ↗
71. Lindsay, K. E. et al. Visualization of early events in mRNA vaccine delivery in non-human primates via PET-CT and near-infrared imaging. Nat. Biomed. Eng. 3, 371–380 (2019).10.1038/s41551-019-0378-3 ↗
72. Oberli, M. A. et al. Lipid nanoparticle assisted mRNA delivery for potent cancer immunotherapy. Nano Lett. 17, 1326–1335 (2016).10.1021/acs.nanolett.6b03329 ↗
73. Yin, Y. et al. Transforming RNA nanovaccines from polyethylenimine functionalized graphene oxide hydrogel for durable cancer immunotherapy. Nano Lett. 21, 2224–2231 (2021).10.1021/acs.nanolett.0c05039 ↗
74. Bitounis, D., Jacquinet, E., Rogers, M. A. & Amiji, M. M. Strategies to reduce the risks of mRNA drug and vaccine toxicity. Nat. Rev. Drug Discov. 23, 281–300 (2024).10.1038/s41573-023-00859-3 ↗
75. Szőke, D. et al. Nucleoside-modified VEGFC mRNA induces organ-specific lymphatic growth and reverses experimental lymphedema. Nat. Commun. 12, 3460 (2021).10.1038/s41467-021-23546-6 ↗
76. Qin, M., Du, G. S. & Sun, X. Recent advances in the noninvasive delivery of mRNA. Acc. Chem. Res. 54, 4262–4271 (2021).10.1021/acs.accounts.1c00493 ↗
77. Hotz, C. et al. Local delivery of mRNA-encoding cytokines promotes antitumor immunity and tumor eradication across multiple preclinical tumor models. Sci. Transl. Med. 13, eabc7804 (2021).10.1126/scitranslmed.abc7804 ↗
78. Patel, A. K. et al. Inhaled nanoformulated mRNA polyplexes for protein production in lung epithelium. Adv. Mater. 31, e1805116 (2019).10.1002/adma.201805116 ↗
79. Zha, S., Wong, K. L. & All, A. H. Intranasal delivery of functionalized polymeric nanomaterials to the brain. Adv. Healthc. Mater. 11, e2102610 (2022).10.1002/adhm.202102610 ↗
80. Bai, C. H., Wang, C. & Lu, Y. Novel vectors and administrations for mRNA delivery. Small 19, e2303713 (2023).10.1002/smll.202303713 ↗
81. Sung, J. S., Alghoul, Z., Long, D. P., Yang, C. H. & Merlin, D. Oral delivery of IL-22 mRNA-loaded lipid nanoparticles targeting the injured intestinal mucosa: a novel therapeutic solution to treat ulcerative colitis. Biomaterials 288, e2307796121 (2022).10.1016/j.biomaterials.2022.121707 ↗
82. Abramson, A. et al. Oral mRNA delivery using capsule-mediated gastrointestinal tissue injections. Matter 5, 975–987 (2022).10.1016/j.matt.2021.12.022 ↗
83. Devoldere, J. et al. Non-viral delivery of chemically modified mRNA to the retina: subretinal intravitreal administration. J. Control. Release 307, 315–330 (2019).10.1016/j.jconrel.2019.06.042 ↗
84. Nabhan, J. F. et al. Intrathecal delivery of frataxin mRNA encapsulated in lipid nanoparticles to dorsal root ganglia as a potential therapeutic for Friedreich’s ataxia. Sci. Rep. 6, 20019 (2016).10.1038/srep20019 ↗
85. Anttila, V. et al. Direct intramyocardial injection of VEGF mRNA in patients undergoing coronary artery bypass grafting. Mol. Ther. 31, 866–874 (2023).10.1016/j.ymthe.2022.11.017 ↗
86. Gao, K. W. et al. In utero delivery of mRNA to the heart, diaphragm and muscle with lipid nanoparticles. Bioact. Mater. 25, 387–398 (2023).
87. Kong, N. et al. Intravesical delivery of KDM6A-mRNA via mucoadhesive nanoparticles inhibits the metastasis of bladder cancer. Proc. Natl Acad. Sci. USA 119, e2112696119 (2022).10.1073/pnas.2112696119 ↗
88. Kon, E., Ad-El, N., Hazan-Halevy, I., Stotsky-Oterin, L. & Peer, D. Targeting cancer with mRNA-lipid nanoparticles: key considerations and future prospects. Nat. Rev. Clin. Oncol. 20, 739–754 (2023).10.1038/s41571-023-00811-9 ↗
89. Lin, L., Su, K., Cheng, Q. & Liu, S. Targeting materials and strategies for RNA delivery. Theranostics 13, 4667–4693 (2023).10.7150/thno.87316 ↗
90. Tsuchida, C. A., Wasko, K. M., Hamilton, J. R. & Doudna, J. A. Targeted nonviral delivery of genome editors in vivo. Proc. Natl Acad. Sci. USA 121, e2307796121 (2024).10.1073/pnas.2307796121 ↗
91. Zhao, X. et al. Imidazole-based synthetic lipidoids for in vivo mRNA delivery into primary T lymphocytes. Angew. Chem. Int. Ed. 59, 20083–20089 (2020).10.1002/anie.202008082 ↗
92. Lokugamage, M. P. et al. Optimization of lipid nanoparticles for the delivery of nebulized therapeutic mRNA to the lungs. Nat. Biomed. Eng. 5, 1059–1068 (2021).10.1038/s41551-021-00786-x ↗
93. Nogueira, S. S. et al. Polysarcosine-functionalized lipid nanoparticles for therapeutic mRNA delivery. ACS Appl. Nano Mater. 3, 10634–10645 (2020).10.1021/acsanm.0c01834 ↗
94. Fu, L. et al. ‘Passive’ nanoparticles for organ-selective systemic delivery: design, mechanism and perspective. Chem. Soc. Rev. 52, 7579–7601 (2023).10.1039/D2CS00998F ↗
95. Kaczmarek, J. C. et al. Optimization of a degradable polymer–lipid nanoparticle for potent systemic delivery of mRNA to the lung endothelium and immune cells. Nano Lett. 18, 6449–6454 (2018).10.1021/acs.nanolett.8b02917 ↗
96. Mi, P., Cabral, H. & Kataoka, K. Ligand-installed nanocarriers toward precision therapy. Adv. Mater. 32, 1902604 (2020).10.1002/adma.201902604 ↗
97. Patel, S. et al. Naturally-occurring cholesterol analogues in lipid nanoparticles induce polymorphic shape and enhance intracellular delivery of mRNA. Nat. Commun. 11, 983 (2020).10.1038/s41467-020-14527-2 ↗
98. Whitehead, K. A., Langer, R. & Anderson, D. G. Knocking down barriers: advances in siRNA delivery. Nat. Rev. Drug Discov. 8, 129–138 (2009).10.1038/nrd2742 ↗
99. Kranz, L. M. et al. Systemic RNA delivery to dendritic cells exploits antiviral defence for cancer immunotherapy. Nature 534, 396–401 (2016).10.1038/nature18300 ↗
100. Radmand, A. et al. Cationic cholesterol-dependent LNP delivery to lung stem cells, the liver, and heart. Proc. Natl Acad. Sci. USA 121, e2307801120 (2024).10.1073/pnas.2307801120 ↗